- Home
- GERN vs CCBG Comparison
GERN vs CCBG Comparison
Compare GERN & CCBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GERN | CCBG |
|---|---|---|
| Founded | 1990 | 1895 |
| Country | United States | United States |
| Employees | 258 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.0M | 877.0M |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | GERN | CCBG |
|---|---|---|
| Price | $1.29 | $51.87 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 1 |
| Target Price | $2.17 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 8.1M | 76.1K |
| Earning Date | 05-06-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 2.34% |
| EPS Growth | N/A | ★ 15.38 |
| EPS | N/A | ★ 0.92 |
| Revenue | N/A | N/A |
| Revenue This Year | $26.91 | $6.25 |
| Revenue Next Year | $43.75 | $3.17 |
| P/E Ratio | ★ N/A | $56.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $38.06 |
| 52 Week High | $2.01 | $53.42 |
Technical Indicators
Market Signals| Indicator | GERN | CCBG |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 58.72 |
| Support Level | $1.24 | $44.48 |
| Resistance Level | $1.46 | N/A |
| Average True Range (ATR) | 0.07 | 1.46 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 6.52 | 57.18 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
About CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services, among others, through its banking offices in Florida, Georgia, and Alabama.